NCT00824291

Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 437 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 19 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (DVS SR) or placebo for 12 weeks.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	desvenlafaxine succinate sustained release	50 mg/day oral tablet for 12 weeks
GENETIC	Genotyping	CYP2D6 genotyping at randomization

Timeline

• Start date: 2009-02-01
• Primary completion: 2009-10-01
• Completion: 2009-11-01
• First posted: 2009-01-16
• Last updated: 2011-03-10
• Results posted: 2010-11-25